98%
921
2 minutes
20
Background: Leprosy is an infectious disease that remains hyperendemic in several Brazilian regions. Patient contacts face a higher risk for infection and illness, which can subsequently contribute to the persistence of the disease.
Objective: This study investigates the risk factors associated with anti-phenolic glycolipid-I (anti-PGL-I) seropositivity and leprosy development among contacts of leprosy patients in a highly endemic region.
Methods: A cohort of 629 contacts from the Almenara microregion, Minas Gerais, Brazil, was followed from 1998 to 2018. Our research group assessed risk factors, including sociodemographic determinants, bacillus exposure, and genetic susceptibility.
Findings: Analysis revealed that living with a multibacillary (MB) leprosy patient [odds ratio (OR): 3.01, 95% confidence interval (CI): 1.02-8.86] and with a patient with grade II disabilities (OR: 4.43, 95% CI: 1.08-18.1) significantly increased the likelihood of anti-PGL-I seropositivity among asymptomatic contacts. Risk factors for leprosy included living with a patient in a shared residence (OR: 2.84, 95% CI: 1.21-6.67) and blood relation to the patient (OR: 2.56, 95% CI: 1.18-5.54). Notably, 98% of contacts who developed leprosy had lived with more than one patient.
Main Conclusions: Clinical characteristics of index patients play a critical role in infection risk among contacts. Leprosy progression appears to depend on genetic susceptibility, type of contact, and extent of bacillus exposure.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12113343 | PMC |
http://dx.doi.org/10.1590/0074-02760240061 | DOI Listing |
Mem Inst Oswaldo Cruz
May 2025
Universidade Federal de Minas Gerais, Escola de Enfermagem, Departamento de Enfermagem Materno-Infantil e Saúde Pública, Belo Horizonte, MG, Brasil.
Background: Leprosy is an infectious disease that remains hyperendemic in several Brazilian regions. Patient contacts face a higher risk for infection and illness, which can subsequently contribute to the persistence of the disease.
Objective: This study investigates the risk factors associated with anti-phenolic glycolipid-I (anti-PGL-I) seropositivity and leprosy development among contacts of leprosy patients in a highly endemic region.
Eur J Clin Microbiol Infect Dis
April 2025
Rapid Test Development and Production Laboratory, Institute of Tropical Pathology and Public Health, Federal University of Goiás, LDPTR/IPTSP/UFG), Goiânia, GO, 74605-050, Brazil.
Purpose: Leprosy represents a public health concern; its diagnosis remains clinical. Recently, the Brazilian public health system/SUS incorporated the leprosy-specific IgM anti-PGL-I rapid test Fast ML Flow Hanseníase (MLFH/Bioclin, Brazil; originally ML Flow) to aid leprosy contacts surveillance and diagnosis. Anti-PGL-I antibody levels correlate with bacterial load.
View Article and Find Full Text PDFInfect Dis Poverty
December 2024
Leiden University Center of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.
Background: Detection of infection with Mycobacterium leprae allows timely prophylactic treatment, thereby reducing transmission as well as the risk of permanent, leprosy-associated nerve damage. However, since there is no worldwide-implemented standard test for M. leprae infection, detection of infection in asymptomatic individuals remains a major challenge for control programs in endemic areas.
View Article and Find Full Text PDFArch Dermatol Res
November 2024
Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Leprosy is a chronic, debilitating disease lacking a definitive diagnostic biomarker. Serum anti-phenolic glycolipid-I (PGL-I) IgM antibody level is considered an important diagnostic and prognostic marker for leprosy patients. However, there is limited evidence on the role of anti-PGL-I IgM antibody level as early predictive biomarker of subclinical infection among Egyptian household contacts of leprosy patients.
View Article and Find Full Text PDFFront Med (Lausanne)
September 2023
Department of Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands.